In Conditions

Follow this topic

Bookmark

Record learning outcomes

Omega Pharma is investing £3 million into the hayfever category following the addition of BecoAllergy to its range. BecoAllergy joins barrier treatment Prevalin Allergy and nasal spray Beconase. Stuart White, marketing manager for the Omega Pharma hayfever portfolio said: €We're delighted to introduce BecoAllergy to our existing portfolio and are committed to supporting pharmacy teams in offering the best advice and recommendations.€

Omega Pharma has invested in a free 'hayfever advice' training booklet and 'quick guide' to help pharmacy teams recommend appropriate treatments for hayfever sufferers. TV advertisements for BecoAllergy will air in June and July.